CClinicalTrials.gg
Enrolling by invitationNCT06413030SGSFUpdated May 14, 2024

Slow Gait Speed as an Indicator of Overweight, Dynapenic Obesity and Sarcopenic Obesity in Elderly People in the Community

An observational study in Frailty, Obesity and Sarcopenia, sponsored by University of Americas. Enrolling by invitation at 1 site in Chile. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by University of Americas · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
383
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the relationship of gait speed with dynapenic or sarcopenic obesity in community-dwelling older people. The main questions it aims to answer are:

  • Is slow walking speed related to overweight in older people in the community?
  • Is slow walking speed related to dynapenic obesity in older people in the community?
  • Is gait speed related to sarcopenic obesity in older people in the community?

Participants will answer a clinical interview to obtain sociodemographic data and will perform the following clinical tests: (1) 10-meter walk test, (2) Anthropometric measurement; (3) Handgrip dynamometry test, (4) Standing dynamometry test and (5) Physical functionality questionnaires.

02

Conditions studied

  • Frailty
  • Obesity
  • Sarcopenia
  • Sarcopenic Obesity
  • Gait Speed

Keywords

  • aged
  • Aged, 80 and over
03

In context

Sarcopenia

1,211 studies on the registry are indexed under Sarcopenia; 403 are open to participants now.

This study's planned enrollment of 383 is above the median of 120 across 421 observational studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

University of Americas is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Older people who live in the community and attend primary health care centers in the Bio Bio Region of Chile.

Inclusion criteria

  • Subjects over 60 years of age
  • Female and male
  • Self-sufficient in the instrumental activities of daily living
  • Subjects with or without drug consumption, capable of carrying out the activity of walking independently or dependent on technical aids.

Exclusion criteria

Exclusion Criteria:

  • Subjects with acute musculoskeletal injuries of the lower extremity.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
383 participants (estimated)
Patient registry
No

Groups and cohorts

  • Community-dwelling older adults

    Persons over 60 years of age attending primary health care centers in the Bio Bio Region of Chile.

    Diagnostic Test: 10 Meter Walk Test

Interventions

  • Diagnostic test10 Meter Walk Test

    Gait Speed Test

06

What researchers measure

Primary outcomes

  1. Gait Speed

    A well-lit, unobstructed flat corridor with an extension of 10 meters is used for the test. Ground markings are added at 0 and 10 meters apart, with 2 meters start (acceleration) and 2 meters end (deceleration) added to allow participants room to accelerate and decelerate their walk outside the data collection area to help reduce the gait variability introduced during these phases. Subjects were instructed to walk at a usual and comfortable speed, without running or stopping. Subjects are allowed to use usual technical aids for walking, including walkers or canes if required. Chronometers based on smartphones to time the route between the second and third line of the route that consists of the 10 timed meters. The stopwatch records the time at which the subject's toe crossed the line. This sequence is repeated three times with 1 minute rest periods. The average of the three trials is used to determine the walking speed.

    Time frame: Month 1

  2. Anthropometric measures

    Biospace Inbody: Individuals are placed in a standing position with 30º flexion of the scapulo-humeral joint. 8 electrodes are used located on: feet (metatarso-calcaneus) and hands (metacarpals 2nd-5th finger and phalanx of the thumb). The induction frequency is assessed with 6 different intensities (1, 5, 50, 250, 500 kHz and 1 MHz), with a fat mass estimation sensitivity of 0.1 kg (0.1%). From this measurement we obtain: percentage of muscle mass, percentage of general fat, percentage of visceral fat and bone weight.

    Time frame: Month 1

  3. Handgrip dynamometry

    To evaluate manual muscle strength, the Baseline handgrip dynamometer will be used. The assessment is carried out with the subject in a seated position in a chair without armrests, with the back and feet adequately supported on the floor while the hips and knees are at 90°. The position was with shoulders adducted and neutrally rotated, elbows flexed at 90° and forearms in a neutral position. We began by evaluating the dominant hand by positioning the wrist between 15 and 30° of extension and between 0° and 15° of ulnar deviation. The dynamometer must be used in a vertical position, and parallel to the forearm, while the participant grips the handle with a thumbs up. 3 repetitions were performed for each limb, obtaining an average of the measurements, the grip time will be 3 to 6 seconds with a rest time of 1 minute, using the best value for data analysis.

    Time frame: Month 1

07

Study locations

1 site
  • Universidad de las Américas
    Concepción, Chile
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413030
Lead sponsor
University of Americas
Responsible party
Karen Córdova-León (Academic Leader, University of Americas) — Principal investigator
First posted
May 14, 2024
Start date
Feb 1, 2024
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 14, 2024

Study contacts

Karen Córdova-León, PT
principal investigator · Academic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion